The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.
作者： Joel E Gallant
DOI:
关键词:
摘要: The M184V mutation is selected by lamivudine (3TC) and emtricitabine (FTC) a common in HIV-infected patients. Virus with the has high level of resistance to 3TC FTC but been shown have favorable effects on susceptibility some other NRTIs can delay clinical immunologic progression decreasing viral fitness. While it always better not any drug so that are available as active antiretroviral agents, important take advantage beneficial when present.
elsevier.com参考文章(20)
Anton L Pozniak, Brian G Gazzard, Bart Winters, Richard Hoetelmans, Neil M Graham, Michael Sproat, Monika Peeters, The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antiviral Therapy. ,vol. 10, pp. 357- 361 ,(2005)
N. K. Back, M. Nijhuis, W. Keulen, C. A. Boucher, B. O. Oude Essink, A. B. van Kuilenburg, A. H. van Gennip, B. Berkhout, Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. The EMBO Journal. ,vol. 15, pp. 4040- 4049 ,(1996) , 10.1002/J.1460-2075.1996.TB00777.X
Helen L. Devereux, Mike Youle, Margaret A. Johnson, Clive Loveday, Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy AIDS. ,vol. 13, pp. 123- 127 ,(1999) , 10.1097/00002030-199912240-00001
Véronique Picard, Emmanuelle Angelini, Anne Maillard, Esther Race, François Clavel, Geneviève Chêne, Françoise Ferchal, Jean‐Michel Molina, Comparison of Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Stavudine and Didanosine or Zidovudine and Lamivudine The Journal of Infectious Diseases. ,vol. 184, pp. 781- 784 ,(2001) , 10.1086/323088
M. A. Wainberg, W. C. Drosopoulos, H. Salomon, M. Hsu, G. Borkow, M. A. Parniak, Z. Gu, Q. Song, J. Manne, S. Islam, G. Castriota, V. R. Prasad, Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. ,vol. 271, pp. 1282- 1285 ,(1996) , 10.1126/SCIENCE.271.5253.1282
Joseph J. Eron, Sharon L. Benoit, Joseph Jemsek, Rodger D. MacArthur, Jorge Santana, Joseph B. Quinn, Daniel R. Kuritzkes, Mary Ann Fallon, Marc Rubin, Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter The New England Journal of Medicine. ,vol. 333, pp. 1662- 1669 ,(1995) , 10.1056/NEJM199512213332502
C A Boucher, N Cammack, P Schipper, R Schuurman, P Rouse, M A Wainberg, J M Cameron, High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. ,vol. 37, pp. 2231- 2234 ,(1993) , 10.1128/AAC.37.10.2231
Lisa Ross, Neil Parkin, Colombe Chappey, Robin Fisher, Marty St Clair, Michael Bates, Margaret Tisdale, Ernest Randall Lanier, Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance AIDS. ,vol. 18, pp. 1691- 1696 ,(2004) , 10.1097/01.AIDS.0000131355.44834.E4
Chris Verhofstede, Filip Van Wanzeele, Bea Van Der Gucht, Nancy De Cabooter, Jean Plum, Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS. ,vol. 13, pp. 2541- 2546 ,(1999) , 10.1097/00002030-199912240-00007
Rob Schuurman, Monique Nijhuis, Remko Van Leeuwen, Pauline Schipper, Dorien De Jong, Phil Collis, Sven A Danner, John Mulder, Clive Loveday, Cindy Christopherson, Shirley Kwok, John Sninsky, Charles AB Boucher, None, Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC) The Journal of Infectious Diseases. ,vol. 171, pp. 1411- 1419 ,(1995) , 10.1093/INFDIS/171.6.1411